- Home
- GNLX vs IMNM Comparison
GNLX vs IMNM Comparison
Compare GNLX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | IMNM |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 2.8B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNLX | IMNM |
|---|---|---|
| Price | $2.57 | $20.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $19.80 | ★ $32.80 |
| AVG Volume (30 Days) | 145.8K | ★ 985.9K |
| Earning Date | 03-19-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $5.15 |
| 52 Week High | $8.54 | $27.65 |
Technical Indicators
Market Signals| Indicator | GNLX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 42.99 |
| Support Level | $2.54 | $19.26 |
| Resistance Level | $3.00 | $22.57 |
| Average True Range (ATR) | 0.15 | 1.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 42.20 | 24.79 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.